Search the Newsreel

KYMR Maintained by Guggenheim -- Price Target Raised to $135

Guggenheim maintained a 'Buy' rating on Kymera Therapeutics (KYMR) and raised its price target from $125 to $135, an 8% increase. Despite the positive analyst outlook, GuruFocus considers KYMR significantly overvalued with a GF Value™ of $24.14 against a current price of $110.04 and …

Guggenheim raises Kymera Therapeutics price target on IRF5 program

Guggenheim has increased its price target for Kymera Therapeutics (NASDAQ: KYMR) to $135 from $125, maintaining a Buy rating, based on the potential of its IRF5 program (KT-579). The firm anticipates significant value if healthy volunteer data for KT-579, a protein degrader targeting the …

Octagon Capital Advisors LP Reduces Position in Kymera Therapeutics, Inc. $KYMR

Octagon Capital Advisors LP significantly reduced its stake in Kymera Therapeutics by 20.6% in the first quarter of 2026, selling 110,000 shares but still retaining 425,000 shares valued at $35.4 million. Despite this reduction, Kymera Therapeutics reported better-than-expected quarterly results and holds a largely …

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of "Moderate Buy" by Brokerages

Kymera Therapeutics (NASDAQ:KYMR) has received a consensus "Moderate Buy" rating from 22 brokerages, with an average 12-month price target of $122.64, exceeding its current price of $110.57. Despite significant insider selling totaling $390.3 million over the past 90 days, the company recently surpassed Q4 …

Form 4 Kymera Therapeutics Inc For: 27 July By Investing.com

This article reports on a Form 4 filing for Kymera Therapeutics Inc, dated July 27. It includes the company's stock symbol, KYMR, and notes a slight decrease in its share price. The content is presented without further financial details beyond the mention of the …

Johnson & Johnson Immunology Leader Joins Kymera as Chief Medical Officer

Kymera Therapeutics has appointed Terence Rooney, MD, as its new Chief Medical Officer, succeeding Jared Gollob, MD, who will transition to an advisory role. Dr. Rooney, formerly an immunology leader at Johnson & Johnson, will guide Kymera's global clinical development strategy and advance its …

Kymera Therapeutics (NASDAQ: KYMR) names Terence Rooney as new CMO

Kymera Therapeutics (NASDAQ: KYMR) has appointed Terence Rooney, M.D., as its new Chief Medical Officer, effective July 27, 2026. Dr. Rooney, a seasoned immunology drug development leader, will lead the company's global clinical development strategy for its oral immunology portfolio. He succeeds Jared Gollob, …

Kymera Therapeutics names Terence Rooney as chief medical officer

Kymera Therapeutics, Inc. (NASDAQ: KYMR) has appointed Terence Rooney, MD, as its new Chief Medical Officer. Dr. Rooney will be responsible for leading the company's global clinical development strategy and advancing its oral immunology portfolio. He previously held senior leadership roles at Johnson & …

Kymera Therapeutics Inc (KYMR) Cash Flow

This article provides access to the annual and quarterly cash flow statements for Kymera Therapeutics Inc (KYMR), allowing users to evaluate the company's financial health. It details operating, investing, and financing cash flows, along with free cash flow, across various fiscal quarters. The content …

Kymera Therapeutics Inc (KYMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Kymera Therapeutics Inc (KYMR), focusing on business segments, regional revenue, and profit contribution. It notes that detailed data for FY2024 and FY2025 have not yet been disclosed by the company, though it does mention a United States …

Kymera Therapeutics Inc (KYMR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Kymera Therapeutics Inc (KYMR), listing its major institutional holders and their respective proportions. It also provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity with changes in holdings for key …

Kymera Therapeutics Inc

Kymera Therapeutics Inc (KYMR) is a clinical-stage biopharmaceutical company focusing on small molecule therapeutics that degrade disease-causing proteins. The company's stock is currently priced at $110.57 and shows strong underlying fundamentals and high growth potential. Analysts have rated KYMR as a Buy, with a …

Is Kymera Therapeutics Poised for a Breakthrough With KT-621?

Kymera Therapeutics is advancing its lead candidate, KT-621, an oral STAT6 degrader for inflammatory diseases. The company recently completed enrollment for its phase IIb study in atopic dermatitis six months ahead of schedule, with pivotal data expected by late 2026. This accelerated timeline and …

Kymera Therapeutics, Inc. (KYMR) Stock Analysis: A Promising Biotech with a 12.68% Upside

Kymera Therapeutics, Inc. (KYMR) is a clinical-stage biopharmaceutical company focused on protein degradation, with a market capitalization of $9.14 billion. The stock trades at $111.06, showing significant volatility but current technical indicators suggest potential growth, with an RSI signalling the stock is oversold. Analysts …

(KYMR) Price Dynamics and Execution-Aware Positioning

This article analyzes Kymera Therapeutics Inc. (NASDAQ: KYMR) stock, highlighting weak near-term sentiment but positive long-term outlooks. It provides specific AI-generated trading strategies including long, breakout, and short positions with defined entry, target, and stop-loss levels. The analysis also details multi-timeframe signal strengths, support, …

Law firm probes Kymera Therapeutics' officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating Kymera Therapeutics, Inc. officers and directors for potential breaches of fiduciary duties through self-dealing. This legal probe aims to secure damages and governance reforms for shareholders. The firm encourages long-term investors in Kymera to seek a free consultation, as …

Kymera Therapeutics Price Target Raised to $140.00/Share From $120.00 by Mizuho

Mizuho has increased its price target for Kymera Therapeutics (NASDAQ:KYMR) to $140.00 per share, up from $120.00. This revised price target suggests a potential upside from the company's previous valuation. Investors and market observers will be watching Kymera Therapeutics' performance following this positive analyst …

Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140

Piper Sandler has reiterated its Buy rating for Kymera Therapeutics (KYMR.US), maintaining a target price of $140. This continued endorsement suggests confidence in the company's future performance.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

Purcell & Lefkowitz LLP has initiated a shareholder investigation into Kymera Therapeutics, Inc. (NASDAQ: KYMR) to determine if its directors breached their fiduciary duties regarding recent corporate actions. Shareholders of Kymera Therapeutics are encouraged to contact the law firm for more information about their …

KYMR Maintained by Mizuho -- Price Target Raised to $140

Mizuho has maintained an "Outperform" rating for Kymera Therapeutics (KYMR) and increased its price target from $120 to $140, reflecting confidence in the company's potential. Despite this positive outlook, GuruFocus indicates that KYMR is significantly overvalued at 385.4% above its intrinsic value, with a …

Kymera Therapeutics (KYMR) AGM 2024 Summary

This article summarizes Kymera Therapeutics' (KYMR) 2024 Annual General Meeting, highlighting the agenda, board and executive updates, and four shareholder proposals discussed. It also provides a quick overview of recent company events and clinical advancements, including progress in STAT6 and TYK2 degrader programs.

Kymera Therapeutics (KYMR) 44th Annual J.P. Morgan Healthcare Conference Summary

Kymera Therapeutics (KYMR) presented its strategic vision and pipeline progress at the 44th Annual J.P. Morgan Healthcare Conference. The company is focused on developing novel oral drugs for immune-inflammatory diseases, aiming to expand access for 160 million patients and revolutionize treatment paradigms. Key pipeline …

Kymera Therapeutics (KYMR) Jefferies London Healthcare Conference 2025 Summary

Kymera Therapeutics (KYMR) presented a summary of its strategic focus and pipeline at the Jefferies London Healthcare Conference 2025. The company is developing oral medicines using targeted protein degradation, primarily in immunology, with a strong focus on its STAT6 program for type II inflammation. …

Kymera Therapeutics (KYMR) Stock Looks Fully Priced After A 405% Run

Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?

Stocks making the biggest moves midday: BlackBerry, Kymera Therapeutics, Apple, Wendy's & more

Kymera Therapeutics KYMR Stock Surges On Sanofi Milestone

Kymera Therapeutics KYMR Stock Jumps On Pipeline Momentum

Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates

Kymera Therapeutics earnings on deck after Gilead deal milestone By Investing.com

The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

Clinical-Stage Biotech Kymera Therapeutics Sets Q2 Earnings Date: Key Updates Expected on Immunology Pipeline